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Abstract
Background: Estimated glomerular filtration rate (eGFR) is a powerful predictor of mortality in diabetic patients
with limited proteinuria data. In this study, we tested whether concomitant proteinuria increases the risk of
mortality among patients with type 2 diabetes.
Methods: Participants included 6523 patients > 30 years with type 2 diabetes who were enrolled in a management
program of a medical center before 2007. Renal function was assessed by eGFR according to the Modification of
Diet in Renal Disease Study equation for Chinese. Proteinuria was assessed by urine dipstick.
Results: A total of 573 patients (8.8%) died over a median follow-up time of 4.91 years (ranging from 0.01 year to
6.42 years). The adjusted expanded cardiovascular disease (CVD)-related mortality rates among patients with
proteinuria were more than three folds higher for those with an eGFR of 60 mL/min/1.73 m2 or less compared with
those with an eGFR of 90 mL/min/1.73 m2 or greater [hazard ratio, HR, 3.15 (95% confidence interval, CI, 2.0–5.1)].
The magnitude of adjusted HR was smaller in patients without proteinuria [1.98 (95% CI, 1.1–3.7)]. An eGFR of
60 mL/min/1.73 m2 to 89 mL/min/1.73 m2 significantly affected all-cause mortality and mortality from expanded
CVD-related causes only in patients with proteinuria. Similarly, proteinuria affected all outcomes only in patients
with an eGFR of <60 mL/min/1.73 m2.
Conclusion: The risks of all-cause mortality, as well as expanded and non-expanded mortality from CVD-related
causes associated with proteinuria or an eGFR of 90 mL/min/1.73 m2 or greater are independently increased.
Therefore, the use of proteinuria measurements with eGFR increases the precision of risk stratification for mortality.
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Introduction
Diabetic nephropathy is the most common cause of end-
stage renal disease (ESRD) worldwide and is the primary
indication for renal replacement therapy in most devel-
oped countries [1,2]. ESRD is strongly associated with car-
diovascular morbidity and mortality [3], thereby putting a
consid0erable burden on healthcare systems worldwide
[1-4]. Meanwhile, the incidence and prevalence rates of
ESRD have continuously increased in Taiwan since 2000
[4]. According to previous epidemiological studies, the key
predictors of chronic kidney disease include age, female
sex, diabetes [5], hypertension [5] or hypertension medica-
tion [5,6], and hyperlipidemia [7]. Meanwhile, diabetes is
rapidly increasing in the Chinese population, especially in
Taiwan, mainland China, Hong Kong, and Singapore,
accounting for at least one-fifth of the global population
[8-11].
Although diabetes is the leading cause of decreased
renal function, diabetes itself is an important predictor
of cardiovascular morbidity and mortality [12]. Several
studies have explored the association between estimated
glomerular filtration rate (eGFR) and all-cause mortality
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and cardiovascular-specific morbidity and mortality
[13-31]. However, the studies were conducted involving
patients with cardiovascular disease [15-20], patients
with impaired kidney function [21,22,32], or a general
population [23-28]. Only a few studies have explored the
relationship between decreased renal function (expressed
as eGFR) and mortality in patients with diabetes
[13,14,29-31], and few studies identified the relationship
between eGFR and CVD-specific mortality [13,31]. In
addition, it has been reported that proteinuria was inde-
pendently associated with cardiovascular events among
patients with type 2 diabetic nephropathy and hyperten-
sion when reduced eGFR was considered [33]. And there
is a need to explore the association between eGFR and
mortality by stratifying proteinuria status in patients with
type 2 diabetes.
The current study aims to examine the association bet-
ween annual eGFR and the all-cause and the expanded,
and non-expanded CVD-related mortalities by stratifying
the proteinuria status in a large cohort of ethnic Chinese
patients with type 2 diabetes, who were followed for
more than 4 years at a single medical center.
Methods
Study population
Patients in this prospective cohort were selected from all
participants of the Diabetes Care Management Program
(DCMP) of the China Medical University Hospital
(CMUH), Taichung, Taiwan. DCMP is a case-mana-
gement program established by the Taiwan Bureau of
National Health Insurance in 2002 that provides an
intervention program aimed at meeting treatment goals
recommended by the American Diabetes Association
(ADA) by tightly controlling multiple factors. All
patients with a clinically confirmed diagnosis of diabetes
mellitus per the ADA criteria (International Classifica-
tion of Diseases, ninth revision, clinical modification,
ICD-9-CM; Diagnosis code 250) were invited to partici-
pate. This program provides financial incentives for phy-
sicians to increase exhaustive follow-up visits, develop
an educational program for diet and life style beha-
viors, and conduct examinations and four laboratory
tests annually. In addition, participants were required
to complete a standardized, computerized questionnaire
administered by a case management nurse to record pre-
vious or current disease status, as well as lifestyle beha-
viors. Patients with type 1 diabetes (ICD-9-CM; Code of
250.x1/x3) and those with an eGFR value of <15 mL/min/
1.73 m2 were excluded.
Participants who were enrolled in the DCMP-CMUH
by the end of August 2007 were identified from an auto-
mated registry. All patients who enrolled in the registry
from August 2002 to August 2006 and had been con-
tinuously enrolled in the program until August 2008 or
until death were included. The inclusion criteria was sti-
pulated for patients with type 2 diabetes who can pro-
vide at least one year of follow-up for eGFR estimation
and one year of follow-up for evaluating the outcome
measures. These criteria were met by 6523 patients with
type 2 diabetes. The study was approved by the Ethics
Review Board of the China Medical University Hospital.
Blood was drawn with minimal trauma from an ante-
cubital vein in the morning after a 12-hour overnight
fasting, and was sent for analysis within four hours of
collection. Biochemical markers, such as serum creati-
nine, fasting plasma glucose (FPG), high-density lipo-
protein cholesterol (HDL-C), and triglycerides were
analyzed with a biochemical autoanalyzer (Beckman
Coulter Synchron System, Lx-20, Fullerton, CA, USA)
at the Clinical Laboratory Department of CMUH.
Serum cholesterol and triglyceride levels were deter-
mined by enzymatic colorimetry. HDL-C and low-
density lipoprotein cholesterol (LDL-C) levels were
measured by direct HDL-C method. Hemoglobin A1C
(glycosylated hemoglobin) was measured using a
boronate-affinity high-performance liquid chromatog-
raphy (HPLC) assay (reference range, 4.6% to 6.5%). The
inter- and intra-assay coefficients of variation (CV) for
HbA1C were 2.91% for the normal level, 1.79% for the
intermediate level, and 1.09% for the high level. Mo-
dification of Diet in Renal Diseases (MDRD) Study
equation was used to estimate GFR based on serum
creatinine levels [34], where estimated GFR (eGFR in
mL/min/1.73 m2) = 186 × (standardized serum crea-
tinine in mg/dl)-1.154 × age-0.203 (× 0.742, if female, and
×1.233 if Chinese) [35]. Decreased eGFR was defined as
eGFR ≤ 60 mL/min/1.73 m2 and > 15 mL/min/1.73 m2
[34], which correspond to stages 3 and 4. Baseline
urine dipstick measurement was used to define pro-
teinuria and was classified as absence (negative urine
dipstick reading), presence (urine dipstick reading trace,
1+, or ≥2+).
Outcome measures
Primary outcome measures were all-cause mortality and
mortality due to expanded and non-expanded CVD-
related disease [36]. Expanded CVD-related disease was
considered because of the high likelihood of classifying
death due to CVD in patients with diabetes as death due
to diabetes, whereas, in patients with diabetes and kid-
ney disease, as death due to kidney disease. Thus, we
derived the composite measures of expanded and non-
expanded CVD mortality by grouping all deaths due to
CVD, diabetes or kidney disease as expanded CVD mor-
tality and the other causes of deaths as non-expanded
CVD mortality, which was first used by Wen et al. [36].
Expanded CVD mortality was defined as deaths due to
CVD (ICD-9-CM; Diagnosis codes 390–459), diabetes
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(ICD-9-CM; Diagnosis code 250), or kidney disease (ICD-
9-CM; Diagnosis code 580–589), whichever occurred first.
The Taiwan National Death Index, a database that con-
tains records of deaths in the Taiwanese population, was
used to identify possible decedents during the follow-up
period. Deaths were confirmed by our registry after they
had been identified. Linking the unique identification
numbers with this computerized file, 596 deaths were
identified in the cohort studied by the end of 2008. Deaths
were coded according to the ICD-9-CM.
Statistical analyses
Patients were stratified into three stages of renal
function based on annual mean eGFR values according
to the Kidney Disease Outcomes Quality Initiative
guidelines as follows: stage 1 (eGFR, ≥ 90 mL/min/
1.73 m2), stage 2 (eGFR, 60 mL/min/1.73 m2 to
89 mL/min/1.73 m2), stage 3 (eGFR, 30 mL/min/
1.73 m2 to 59 mL/min/1.73 m2), and stage 4 (eGFR,
15 mL/min/1.73 m2 to 29 mL/min/1.73 m2).
Kaplan-Meier cumulative incidence plots were generated,
showing time-to-event for all end points. Time-dependent
Cox proportional hazards models were used to evaluate the
association between the stages of renal function and mortal-
ity by considering the time-varying stage of renal function.
Hazard ratios and their 95% confidence intervals (CI) of
eGFR and proteinuria were calculated by adjusting for age
and multiple variables. Two multivariate models were used.
The first multivariate model adjusted for age (continuous),
hypertension (yes, no), antihypertensive treatment (yes, no),
Figure 1 Mean annual eGFR according to (A) survival status, (B) status of expanded CVD-mortality, and (C) status of non-expanded
CVD-mortality.
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Table 1 Comparisons of baseline sociodemographic factors, lifestyle behaviors, diabetes-related variables, drug-related
variables, diabetes-related diseases, and blood biochemical indices among patients with different clinical stages of
baseline renal function, as determined by mean eGFR
Variables Baseline mean eGFR N (%) P value
≥90 (N=3686) 60~89 (N=1981) 15~59 (N=856)
Sociodemographic factors
Gender 0.01
Female 1800 (48.83) 898 (45.33) 432 (50.47)
Male 1886 (51.17) 1083 (54.67) 424 (49.53)
Age (yrs)† 54.16±10.96 64.19±10.18 67.22±10.09 <0.001
Lifestyle behaviors
Smoking <0.001
No 2863 (77.67) 1665 (84.05) 724 (84.58)
Yes 823 (22.33) 316 (15.95) 132 (15.42)
Alcohol drinking <0.001
No 3200 (86.81) 1784 (90.06) 810 (94.63)
Yes 486 (13.19) 197 (9.94) 46 (5.37)
Exercising <0.001
No 1650 (44.76) 702 (35.44) 304 (35.51)
Yes 2036 (55.24) 1279 (64.56) 552 (64.49)
Diabetes-related variables
Diabetes medical history(yrs)† 5.22±6.06 7.26±7.11 11.23±8.57 <0.001
Type of DM treatment <0.001
Oral hypoglycemic drug 3045 (82.61) 1706 (86.12) 659 (76.99)
Inject insulin 69 (1.87) 15 (0.76) 10 (1.17)
Both 261 (7.08) 159 (8.03) 167 (19.51)
Both not 311 (8.44) 101 (5.10) 20 (2.34)
Drug-related variables
Hypertension drug treatment <0.001
No 2543 (68.99) 953 (48.11) 295 (34.46)
Yes 1143 (31.01) 1028 (51.89) 561 (65.54)
Diabetes-related diseases
Obesity 0.18
No 2581 (70.02) 1346 (67.95) 580 (67.76)
Yes 1105 (29.98) 635 (32.05) 276 (32.24)
Hypertension <0.001
No 2517 (68.29) 967 (48.81) 305 (35.63)
Yes 1169 (31.71) 1014 (51.19) 551 (64.37)
Hyperlipidemia <0.001
No 2637 (71.54) 1317 (66.48) 549 (64.14)
Yes 1049 (28.46) 664 (33.52) 307 (35.86)
DKA 0.72
No 3644 (98.86) 1963 (99.09) 847 (98.95)
Yes 42 (1.14) 18 (0.91) 9 (1.05)
HHNK <0.001
No 3642 (98.81) 1926 (97.22) 813 (94.98)
Yes 44 (1.19) 55 (2.78) 43 (5.02)
Severe Hypoglycemia <0.001
No 3624 (98.32) 1942 (98.03) 810 (94.63)
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smoking (yes, no), obesity (yes, no), alcohol consumption
(yes, no), exercise (yes, no), duration of diabetes, hyper-
lipidemia (yes for total cholesterol ≥ 200 mg/dl, or tri-
glycerides ≥ 150 mg/dl, no), type of treatment (oral
hypoglycemic drug, insulin injection, both, or both not),
and HbA1C. In addition to the variables in the first model,
the second model adjusted for complications at the baseline
(diabetic ketoacidosis, hyperglycemia hyperosmolar non-
ketoacidosis, severe hypoglycemia, stroke, myocardial in-
farction, peripheral neuropathy, intermittent claudication,
and neuropathy). The P values for the trends in annual
mean eGFR across stages were calculated. All P values were
two-tailed, and P < 0.05 was considered statistically signifi-
cant. All analyses were performed using the statistical pack-
age SAS for Windows (Version 9.2, SAS, Cary, NC, USA).
Results
The mean follow-up was 4.31 years. Among the 6523
patients, 573 died during the follow-up period. The
crude mortality rate was 20.37 per 1000 person-years
(24.78 per 1000 person-years for men and 15.75 per
1000 person-years for women). Cancer was the leading
cause of death (n=166, crude rate = 5.90 per 1000 per-
son-years), followed by diabetes (n=132, crude rate =
4.69 per 1000 person-years), and cardiovascular disease
(n=105, crude rate = 3.73 per 1000 person-years). These
causes accounted for a total of 70.33% of all deaths.
Among the patients with type 2 diabetes, 2023, 1355,
927, 791, and 1427 patients provided 1,2, 3, 4, and ≥5
years of annual eGFR measurements, respectively. The
correlation coefficients among annual eGFR from years
1 to 5 ranged from 0.78 to 0.94. Figure 1 shows the
means and standard errors of eGFR from years 1 to 5
according to the statuses of all-cause mortality and mor-
tality due to expanded and non-expanded CVD-related
disease. Individuals with all-cause mortality and mortal-
ity due to expanded and non-expanded CVD-related dis-
ease were associated with lower levels of eGFR from
years 1 to 5.
Baseline eGFR ≥ 90 mL/min/1.73 m2 was associated
with lower mean age, shorter duration of diabetes medi-
cation, lower levels of triglyceride, higher levels of HDL-
Table 1 Comparisons of baseline sociodemographic factors, lifestyle behaviors, diabetes-related variables, drug-related
variables, diabetes-related diseases, and blood biochemical indices among patients with different clinical stages of
baseline renal function, as determined by mean eGFR (Continued)
Yes 62 (1.68) 39 (1.97) 46 (5.37)
Stroke <0.001
No 3522 (95.55) 1799 (89.80) 722 (84.35)
Yes 164 (4.45) 202 (10.20) 134 (15.65)
Coronary artery disease <0.001
No 3546 (96.20) 1799 (90.81) 726 (84.81)
Yes 140 (3.80) 182 (9.19) 130 (15.19)
Myocardial infarction <0.001
No 3414 (92.62) 1805 (91.12) 748 (87.38)
Yes 272 (7.38) 176 (8.88) 108 (12.62)
Peripheral neuropathy <0.001
No 3201 (86.84) 1660 (83.80) 600 (70.09)
Yes 485 (13.16) 321 (16.20) 256 (29.91)
Intermittent claudication <0.001
No 3641 (98.78) 1946 (98.23) 829 (96.85)
Yes 45 (1.22) 35 (1.77) 27 (3.15)
Neuropathy <0.001
No 3461 (93.90) 1823 (92.02) 696 (81.31)
Yes 225 (6.10) 158 (7.98) 160 (18.69)
Blood biochemical indexes
Triglyceride (mg/dl) † 159.98±205.49 166.44±191.09 190.26±216.96 <0.001
High-density lipoprotein (mg/dl) † 41.76±11.31 40.15±10.91 39.30±11.68 <0.001
HbA1c (%)† 8.59±2.01 8.11±1.89 8.26±1.92 <0.001
Fasting plasma glucose (mg/dl) † 169.61±58.40 161.14±59.83 162.37±69.18 <0.001
†:mean±SD; DDK: Diabetic ketoacidosis; HHNK: Hyperglycemia hyperosmolar non-ketoacidosis.
Differences in continuous variables were tested by the student’s t-test.
Differences in categorical variables were tested by the Chi-square test.
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C, HbA1c and FPG, and higher prevalence of smoking
and alcohol drinking statuses, and lower prevalence of
exercise, taking oral hypoglycemic agents and insulin,
hypertension, hyperlipidemia, hyperglycemia hyperos-
molar non-ketoacidosis, severe hypoglycemia, stroke,
coronary artery disease, myocardial infarction, peripheral
neuropathy, intermittent claudication, and neuropathy
(Table 1).
Figure 2 presents the Kaplan-Meier survival curves for
all-cause and expanded and non-expanded CVD-related
mortality within the subgroups defined by the baseline
eGFR. Median survival ranged from 4.83 years for
patients with eGFR ranging from 15 mL/min/1.73 m2 to
59 mL/min/1.73 m2 to 4.66 years for patients with eGFR
≥ 90 mL/min/1.73 m2. Baseline eGFR was a powerful
predictor of all-cause mortality, as well as for both
expanded and non-expanded CVD-related mortalities.
Patients with eGFR values ranging from 15 mL/min/
1.73 m2 to 59 mL/min/1.73 m2 were at increased
risk of death (log-rank p<0.001, Figure 2a), mainly
from expanded (log-rank p<0.001, Figure 2b) and
non-expanded CVD-related causes (log-rank p<0.001,
Figure 2c).
Table 2 shows the hazard ratios (HRs) of mortality
resulting from all causes, as well as from expanded and
non-expanded CVD-related causes according to the
stages of mean annual eGFR and proteinuria. Patients
with a mean annual eGFR of 15 mL/min/1.73 m2 to
P=<0.001 
(a) (c) 
(b) 
P=<0.001 
P=<0.001 
Figure 2 Survival curves of (a) death from all causes, (b) from expanded CVD, and (c) from non-expanded CVD for baseline eGFR of
various clinical stages.
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59 mL/min/1.73 m2 were at a 2.37-fold greater risk of
all-cause mortality (95% CI, 1.88–2.99), a 2.74-fold
greater risk of expanded CVD-related mortality (95% CI,
1.92–3.90), and at a 2.13-fold greater risk of non-
expanded CVD-related mortality (95% CI, 1.56–2.91)
compared with patients with a mean annual eGFR ≥ 90
mL/min/1.73 m2after considering age, lifestyle behaviors,
medications, glucose control, and complications. The
corresponding HRs of proteinuria for all-cause and for
both expanded and non-expanded CVD-related mortal-
ities were 1.55 (95% CI, 1.28–1.87), 1.63 (95% CI, 1.22–
2.16), and 1.49 (95% CI, 1.16–1.92). Significant linear
trends were found across the stages of annual mean
eGFR for all-cause mortality, and mortality due to
expanded and non-expanded CVD-related causes.
Table 3 shows the adjusted HR of all-cause mortality,
mortality due to expanded and nonexpanded CVD-
related causes for patients with an eGFR of 15–59.9 mL/
min/1.73 m2 and 60–89 mL/min/1.73 m2 compared with
those with an eGFR of 90 mL/min/1.73 m2or greater
across the strata of proteinuria. Similarly, Table 4 shows
the adjusted HRs of proteinuria for all-cause mortality
and mortality due to expanded and non-expanded CVD-
related causes were reported across strata of eGFR
categories of 15–59, 60–89, and ≥90 mL/min/1.73 m2.
We did not detect any significant interaction effects of
eGFR and proteinuria on all-cause mortality and mortal-
ity due to expanded and non-expanded CVD-related
causes.
Discussion
In this prospective study, a lower annual eGFR is predic-
tive of all-cause as well as expanded and non-expanded
CVD-related mortalities in patients with diabetes. The
predictive ability of a lower annual eGFR values was based
on the presence of proteinuria. Similarly, the predictive
ability of proteinuria was based on the stages of renal
function measured by eGFR. This finding is important
because the current guidelines for the classification and
staging of chronic kidney disease are based on eGFR,
without considering concomitant proteinuria. Our fin-
dings provide the estimates of the risk stratification by
eGFR along with proteinuria for Chinese patients with
type 2 diabetes.
Our finding that lower GFR values are associated with
a higher risk of all-cause mortality is consistent with pre-
vious studies [13,14,29-31]. In addition, studies have
shown that lower eGFR values are associated with about
Table 2 Hazard ratios (HRs) of all-cause mortality and mortality due to expanded and non-expanded CVD-related
causes based on the clinical stage of the time-dependent annual mean eGFR
Variables All-cause
mortality
P for trend Expanded
CVD-related
mortality
P for trend Non-expanded
CVD-related
mortality
P for trend
HR
(95% CI)
HR
(95% CI)
HR
(95% CI)
Age-adjusted
Annual mean eGFR (mL/min/1.73m2) <0.001 <0.001 <0.001
≥90 1.00 1.00 1.00
60~89 1.23 (0.99-1.53) 1.41 (1.00-2.00)* 1.13 (0.85-1.51)
15~59 2.37 (1.90-2.97)*** 2.90 (2.07-4.10)*** 2.04 (1.51-2.75)***
Proteinuria 1.83 (1.53-2.19)*** 1.99 (1.52-2.61)*** 1.71 (1.35-2.18)***
Multivariate-adjusted1
Annual mean eGFR (mL/min/1.73m2) <0.001 <0.001 <0.001
≥90 1.00 1.00 1.00
60~89 1.33 (1.07-1.66)* 1.55 (1.09-2.19)* 1.21 (0.90-1.62)
15~59 2.49 (1.98-3.14)*** 3.01 (2.12-4.28)*** 2.16 (1.59-2.94)***
Proteinuria 1.62 (1.35-1.95)*** 1.75 (1.33-2.31)*** 1.53 (1.20-1.95)***
Multivariate-adjusted2
Annual mean eGFR (mL/min/1.73m2) <0.001 <0.001 <0.001
≥90 1.00 1.00 1.00
60~89 1.31 (1.05-1.63)* 1.50 (1.06-2.12)* 1.20 (0.90-1.62)
15~59 2.37 (1.88-2.99)*** 2.74 (1.92-3.90)*** 2.13 (1.56-2.91)***
Proteinuria 1.55 (1.28-1.87)*** 1.63 (1.22-2.16)*** 1.49 (1.16-1.92)**
Multivariate-adjusted1 age, duration of diabetes, smoking, alcohol drinking, exercising, hypertension, hypertension drug treatment, obesity, hyperlipidemia, type of
DM treatment, and HbA1C. Multivariate-adjusted
2 DKA, HHNK, severe hypoglycemia, stroke, myocardial infarction, peripheral neuropathy, intermittent claudication,
and neuropathy in addition to variables in model 1.
*p<0.05; **p<0.01; ***p<0.001.
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a 3-fold higher risk of CVD mortality. Similar results
were observed between the current study and those of
Casale Monferrato Study and Nag et al., and the associa-
tion in the Casale Monferrato Study did not reach statis-
tical significance. In addition to more precise results,
three major advantages were obtained using the metho-
dology in the present study. One is that we measured
time-varying mean annual eGFR. Second, previous stu-
dies did not consider co-morbidities and complications
when they explored these associations. The possibility
that co-morbidities and complications may explain the
relationships observed was ruled out by further consi-
dering the effects of co-morbidities and complications.
The associations still remained significant, although the
effect was attenuated. Third, previous studies did not
use both proteinuria and eGFR to predict mortality. This
information would be potentially useful in informing
ongoing discussions about how best to stratify the risk
of mortality among patients with type 2 diabetes using
both proteinuria and eGFR.
Several plausible explanations for the association
between decreased renal function and mortality were
identified. First, diabetic patients with decreased renal
function have a higher prevalence of several CVD risk
factors, including hypertension, dyslipidemia, and obe-
sity, as well as complications. In our study, the preva-
lence of hypertension was 2.14 times higher, 1.29 times
higher for dyslipidemia, 1.12 times higher for obesity,
3.55 times higher for stroke, 4.00 times higher for coro-
nary artery disease, and 1.71 for myocardial infarction
among patients with eGFR < 60 mL/min/1.73 m2 than
among patients with eGFR ≥90 mL/min/1.73 m2. These
chronic conditions resulted in decreased renal function.
Decreased renal function itself may exert an indepen-
dent effect on mortality. Another possible explanation is
that decreased renal function results in lower clearance
and higher plasma levels of inflammatory and oxidative
stress factors, such as homocysteine and asymmetric
dimethylarginine [37]. These unmeasured factors may
explain the higher risk of mortality in patients with
decreased renal function. In addition, decreased renal
function may exacerbate hypertension and activate the
rennin-angiotensin system [38], which may also increase
the risk of mortality. These two biological mechanisms
both aggravate atherosclerotic burden and potentially
increase the risk of CVD.
Table 3 Hazard ratios (HRs) of all-cause mortality and mortality due to expanded and non-expanded CVD-related
causes according to clinical stage of time-dependent annual mean eGFR stratified by proteinuria status (n=6,523)
HR (95% CI)
Without proteinuria (n=4,266) Proteinuria (N=2,257)
Variables n All-cause
mortality
Expanded
CVD-related
mortality
Non-expanded
CVD-related
mortality
n All-cause
mortality
Expanded
CVD-related
mortality
Non-expanded
CVD-related
mortality
Age-adjusted
Annual mean eGFR (mL/min/1.73m2)
≥90 2787 - - - 899 -
60~89 1225 1.02 (0.75-1.39) 1.16 (0.72-1.86) 0.93 (0.62-1.40) 756 1.42 (1.03-1.96)* 1.62 (0.97-2.71) 1.31 (0.86-2.00)
15~59 254 2.22 (1.56-3.18)*** 2.20 (1.26-3.83)** 2.28 (1.43-3.63)*** 602 2.51 (1.86-3.39)*** 3.36 (2.11-5.37)*** 1.99 (1.34-2.96)***
P for trend <0.001 0.01 0.009 <0.001 <0.001 <0.001
Multivariate-adjusted1
Annual mean eGFR (mL/min/1.73m2)
≥90 2787 - - - 899 -
60~89 1225 1.13 (0.82-1.54) 1.33 (0.82-2.16) 1.00 (0.66-1.52) 756 1.56 (1.12-2.16)** 1.76 (1.05-2.95)* 1.45 (0.94-2.22)
15~59 254 2.46 (1.69-3.57)*** 2.62 (1.47-4.70)** 2.39 (1.46-3.89)*** 602 2.58 (1.90-3.51)*** 3.28 (2.04-5.29)*** 2.14 (1.42-3.22)***
P for trend <0.001 0.003 0.005 <0.001 <0.001 <0.001
Multivariate-adjusted2
Annual mean eGFR (mL/min/1.73m2)
≥90 2787 - - - 899 - - -
60~89 1225 1.11 (0.81-1.52) 1.28 (0.79-2.08) 1.01 (0.67-1.53) 756 1.53 (1.10-2.12)* 1.70 (1.02-2.86)* 1.43 (0.94-2.20)
15~59 254 2.23 (1.51-3.30)*** 1.98 (1.06-3.69)* 2.47 (1.49-4.10)*** 602 2.49 (1.83-3.39)*** 3.15 (1.96-5.09)*** 2.06(1.37-3.12)***
P for trend <0.001 0.04 0.006 <0.001 <0.001 <0.001
Multivariate-adjusted1 age, duration of diabetes, smoking, alcohol drinking, exercising, hypertension, hypertension drug treatment, obesity, hyperlipidemia and
type of DM treatment and HbA1C. Multivariate-adjusted
2 DKA, HHNK, severe hypoglycemia, stroke, myocardial infarction, peripheral neuropathy, intermittent
claudication and neuropathy in addition to variables in model 1.
*:p<0.05; **:p<0.01; ***:p<0.001.
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Table 4 Hazard ratios (HRs) of proteinuria for all-cause mortality and mortality due to expanded and non-expanded CVD-related causes stratified by eGFR
status (n=6,523)
Baseline mean eGFR HR (95% CI)
≥90 (N=3,686) 60~89 (N=1,981) 15~59 (N=856)
Variables n All-
cause
mortality
Expanded
CVD-related
mortality
Non-
expanded
CVD-related
mortality
n All-cause
mortality
Expanded
CVD-related
mortality
Non-
expanded
CVD-related
mortality
n All-cause
mortality
Expanded
CVD-related
mortality
Non-
expanded
CVD-related
mortality
Age-adjusted
Proteinuria
No 2,787 1.00 1.00 1.00 1,225 1.00 1.00 1.00 254 1.00 1.00 1.00
Yes 899 1.60** (1.17-2.19) 2.10** (1.29-3.41) 1.33 (0.88-2.01) 756 2.35*** (1.79-3.10) 2.47*** (1.64-3.72) 2.26*** (1.56-3.29) 602 2.51*** (1.72-3.67) 2.70*** (1.55-4.70) 2.32** (1.37-3.93)
Multivariate-adjusted1
Proteinuria
No 2,787 1.00 1.00 1.00 1,225 1.00 1.00 1.00 254 1.00 1.00 1.00
Yes 899 1.34 (0.97-1.86) 1.78* (1.08-2.93) 1.11 (0.73-1.70) 756 2.09*** (1.58-2.77) 2.18*** (1.44-3.32) 2.03*** (1.38-2.97) 602 2.31*** (1.56-3.40) 2.39** (1.36-4.21) 2.17** (1.27-3.72)
Multivariate-adjusted2
Proteinuria
No 2,787 1.00 1.00 1.00 1,225 1.00 1.00 1.00 254 1.00 1.00 1.00
Yes 899 1.17 (0.83-1.66) 1.40 (0.80-3.46) 1.02 (0.65-1.60) 756 1.92*** (1.43-2.58) 1.96** (1.27-3.03) 1.93** (1.30-2.87) 602 2.37*** (1.60-3.52) 2.41** (1.36-4.28) 2.29** (1.33-3.95)
Multivariate-adjusted1 age, duration of diabetes, smoking, alcohol drinking, exercising, hypertension, hypertension drug treatment, obesity, hyperlipidemia and type of DM treatment and HbA1C. Multivariate-adjusted
2
DKA, HHNK, severe hypoglycemia, stroke, myocardial infarction, peripheral neuropathy, intermittent claudication and neuropathy in addition to variables in model 1.
*:p<0.05; **:p<0.01; ***:p<0.001.
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Our findings have several clinical implications. First,
decreased renal function is an important indicator of
renal function in patients with diabetes. Proteinuria sta-
tus, serum creatinine concentrations, and eGFR values
of these patients should be routinely monitored. Second,
lifestyle intervention and use of medications that can
prevent the deterioration of renal function should be
emphasized in diabetes care.
Our study has several strengths, including a large
number of patients with diabetes, a long follow-up per-
iod, the use of a standardized procedure for data col-
lection, and available information on a large number of
potential confounding factors. In addition, we averaged
repeated eGFR measurements to reduce random varia-
tion of measurement errors and improve precision. We
also used time-varying eGFR to increase the accuracy of
renal function measurement.
Our study has several limitations that need to be consi-
dered when interpreting our results. First, we did not
screen other measures of impaired kidney function, such
as microalbuminuria or cystatin C. Microalbuminuria may
be a better marker of early kidney dysfunction, and cysta-
tin C may be a better marker of chronic kidney disease
than creatinine. Second, we used the MDRD equation to
estimate GFR based on serum creatinine levels. Creatinine
levels are affected by differences in muscle mass, and mus-
cle mass distribution varies across gender and age. Al-
though the MDRD equation was developed to consider
population differences in muscle mass by age and gender,
it does not consider individual differences [39]. Third,
despite adjustments for a large number of potential con-
founders, including lifestyle behaviors, medications, and
complications, residual and unrecognized confounding
may be present because of the observational nature of our
study. Lastly, all patients with type 2 diabetes in this study
were enrolled in a Diabetes Care Management Program at
a single medical center; thus, they may not be representa-
tive of all diabetic patients in Taiwan. In order to evaluate
generalizability, we compare the age and gender distribu-
tions between the age and gender structure in our study
and the national population with type 2 diabetes that was
enrolled in the Nation Health Insurance program, which
has a coverage rate of more than 99%. Similar distribu-
tions were found; the differences in proportions for cate-
gories of age and gender distributions between these two
groups ranged from 0.56% to 5.24%. The non-differential
distributions in age and sex indicate the representativeness
of our study sample.
In conclusion, proteinuria and eGFR are independently
predictive of all-cause and both expanded and non-
expanded CVD-related mortalities in patients with type
2 diabetes, supporting the importance of renal function
in mortality prevention. Furthermore, risk stratification
by eGFR alone may be relatively insensitive to clinically
relevant risk gradients. Therefore, the use of proteinuria
measurement with eGFR increases the precision of risk
stratification for mortality.
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